Publication in JCO and ESMO presentation provide peer-reviewed validation of tovecimig's Phase 2/3 data. Key catalyst to watch is the company's next regulatory interaction with the FDA regarding a potential BLA submission for tovecimig in second-line BTC. The crossover-adjusted OS HR of 0.85 (non-significant) is a potential overhang, but the strong PFS and ORR data support the regulatory path.
Price Chart
Executive Summary
Compass Therapeutics announced publication of positive Phase 2/3 COMPANION-002 results for tovecimig in advanced biliary tract cancer in the Journal of Clinical Oncology, with the study meeting its primary endpoint of ORR (18.0% vs 5.3%, p=0.0228) and key secondary endpoint of PFS (HR=0.44, p<0.0001), representing a 56% reduction in risk of progression or death. The company states it will continue working with the FDA toward approval, though tovecimig remains investigational and not yet approved.
Key Facts
- COMPANION-002 met primary endpoint ORR: 18.0% tovecimig + paclitaxel vs 5.3% paclitaxel alone (p=0.0228) by BICR
- Key secondary endpoint PFS met: median 4.7 vs 2.6 months, HR=0.44 (p<0.0001), 56% risk reduction
- Disease control rate significantly improved: 62.2% vs 36.8% (p=0.0018)
- Median duration of response: 4.9 months
- Intrahepatic cholangiocarcinoma subgroup: ORR 15.3% vs 0% (p=0.0258), median PFS 5.1 vs 3.0 months (HR=0.32)
- Crossover-adjusted OS analysis (Two-Stage Estimation): HR 0.85 (95% CI 0.59-1.26, p=0.53)
- Tovecimig has received Fast Track and Orphan Drug Designation from the FDA
- BTC affects approximately 26,500 patients annually in the US; no FDA-approved second-line treatment for non-actionable mutation patients
Financial Impact
No financial figures provided; tovecimig is investigational and not yet approved. BTC market opportunity is ~26,500 patients annually in the US with no approved second-line therapy for the majority.
Risk Factors
- Tovecimig remains investigational and not yet approved by the FDA
- Crossover-adjusted OS analysis showed HR 0.85 with p=0.53, not statistically significant
- Grade 3+ TEAEs occurred in 93.5% of combination arm vs 64.2% control; discontinuation rate 27.8% vs 11.3%
- TEAEs leading to death: 5.6% combination vs 1.9% control
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3387662 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 24, 2026 2d ago | Press Release | $0.7697 | awaiting T+20 | — | $0.7472 (−2.92%) |
Sep 22, 2026 4w ago | 8-K | $1.24 $0.8330 | ▲ +32.82% | ▲ +32.26% | $0.7472 (+39.74%) |
Aug 21, 2026 9w ago | Institutional Cluster | $2.40 $1.90 | ▼ −20.83% | ▼ −20.55% | $0.7472 (−68.87%) |
Aug 6, 2026 11w ago | 8-K | $1.99 $2.37 | ▲ +19.10% | ▲ +18.50% | $0.7472 (−62.45%) |
Aug 6, 2026 11w ago | Press Release | $1.99 $2.37 | ▲ +19.10% | ▲ +18.50% | $0.7472 (−62.45%) |
Jul 17, 2026 14w ago | Press Release | $2.05 $2.25 | ▲ +9.76% | ▲ +5.31% | $0.7472 (−63.55%) |
Jul 1, 2026 16w ago | 8-K | $2.27 $1.94 | ▼ −14.54% | ▼ −14.12% | $0.7472 (−67.08%) |
Jun 11, 2026 19w ago | Institutional Cluster | $2.03 $2.33 | ▲ +14.78% | ▲ +13.00% | $0.7472 (−63.19%) |
May 21, 2026 22w ago | Press Release | $2.07 $2.09 | ▲ +0.72% | ▲ +2.14% | $0.7472 (−63.90%) |
May 5, 2026 24w ago | 8-K | $1.95 $2.08 | ▲ +6.67% | ▲ +1.71% | $0.7472 (−61.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers